Integra LifeSciences Holdings Corp. (NASDAQ:IART)’s share price reached a new 52-week high during mid-day trading on Friday . The company traded as high as $85.43 and last traded at $85.14, with a volume of 69,280 shares changing hands. The stock had previously closed at $84.60.

A number of equities analysts recently issued reports on IART shares. Lake Street Capital boosted their price objective on Integra LifeSciences Holdings Corp. from $57.00 to $75.00 and gave the company a “hold” rating in a report on Thursday, April 28th. Jefferies Group restated a “buy” rating on shares of Integra LifeSciences Holdings Corp. in a report on Thursday, April 28th. Barclays PLC boosted their price objective on Integra LifeSciences Holdings Corp. from $77.00 to $84.00 and gave the company an “equal weight” rating in a report on Friday, July 29th. Zacks Investment Research cut Integra LifeSciences Holdings Corp. from a “buy” rating to a “hold” rating in a report on Friday. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $85.00 price objective on shares of Integra LifeSciences Holdings Corp. in a report on Friday, June 24th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $81.75.

The firm has a 50 day moving average price of $79.77 and a 200 day moving average price of $69.87. The company has a market capitalization of $3.17 billion and a PE ratio of 351.03.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.79 EPS for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.03. The company had revenue of $249.30 million for the quarter, compared to analysts’ expectations of $243.17 million. The business’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.79 EPS. On average, equities analysts anticipate that Integra LifeSciences Holdings Corp. will post $3.48 earnings per share for the current fiscal year.

In related news, VP Joseph Vinhais sold 972 shares of Integra LifeSciences Holdings Corp. stock in a transaction that occurred on Monday, May 9th. The stock was sold at an average price of $73.36, for a total transaction of $71,305.92. Following the transaction, the vice president now owns 4,311 shares in the company, valued at $316,254.96. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Richard D. Gorelick sold 4,000 shares of Integra LifeSciences Holdings Corp. stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $84.60, for a total value of $338,400.00. Following the transaction, the vice president now owns 9,702 shares in the company, valued at approximately $820,789.20. The disclosure for this sale can be found here.

Other institutional investors recently made changes to their positions in the company. State of Tennessee Treasury Department bought a new position in shares of Integra LifeSciences Holdings Corp. during the fourth quarter worth approximately $1,501,000. New York State Common Retirement Fund increased its position in shares of Integra LifeSciences Holdings Corp. by 3.9% in the fourth quarter. New York State Common Retirement Fund now owns 26,400 shares of the company’s stock worth $1,789,000 after buying an additional 1,000 shares during the last quarter. Comerica Bank increased its position in shares of Integra LifeSciences Holdings Corp. by 1.4% in the fourth quarter. Comerica Bank now owns 29,922 shares of the company’s stock worth $1,965,000 after buying an additional 401 shares during the last quarter. Rhumbline Advisers increased its position in shares of Integra LifeSciences Holdings Corp. by 6.6% in the fourth quarter. Rhumbline Advisers now owns 45,298 shares of the company’s stock worth $3,070,000 after buying an additional 2,820 shares during the last quarter. Finally, Foresters Investment Management Company Inc. bought a new position in shares of Integra LifeSciences Holdings Corp. during the fourth quarter worth approximately $5,050,000.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.